Drugs / BOS-475
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04221906 | Jan → Mar 2020 | psoriasis | Boston Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03960450 | Apr 2019 → Jan 2020 | psoriasis | Boston Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BOS-475 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04221906 ↗ |
| Route | Topical | “single and repeat topical administration of BOS-475” NCT03960450 ↗ |